Jacobs Levy Equity Management, Inc Nurix Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 43,863 shares of NRIX stock, worth $561,446. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,863Holding current value
$561,446% of portfolio
0.0%Shares
10 transactions
Others Institutions Holding NRIX
# of Institutions
184Shares Held
77.6MCall Options Held
99.8KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$87.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$77.5 Million1.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.49MShares$57.5 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$49.7 Million0.29% of portfolio
-
Commodore Capital LP New York, NY3.78MShares$48.4 Million2.23% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $603M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...